Singapore markets close in 4 hours 42 minutes
Straits Times Index
3,292.71 +26.76 (+0.82%) Nikkei
38,240.17 +166.19 (+0.44%) Hang Seng
18,859.60 +321.79 (+1.74%) FTSE 100
8,381.35 +27.30 (+0.33%) Bitcoin USD
62,846.32 +1,126.13 (+1.82%) CMC Crypto 200
1,351.61 +51.51 (+3.96%)
Castle Biosciences, Inc. (CSTL)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 23.54 |
| Open | 23.38 |
| Bid | 24.38 x 100 |
| Ask | 24.50 x 200 |
| Day's range | 23.22 - 25.23 |
| 52-week range | 9.26 - 26.70 |
| Volume | |
| Avg. volume | 255,804 |
| Market cap | 674.168M |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
FRIENDSWOOD, Texas, May 08, 2024--Castle announced data supporting the utility of the PRAME biomarker as a risk refinement tool when considered in the context of a DecisionDx-UM result
- Business Wire
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
FRIENDSWOOD, Texas, May 03, 2024--Castle Biosciences will share new data supporting the utility of its DecisionDx®-SCC test at the ACMS Annual Meeting in Phoenix.
- Business Wire
Castle Biosciences Reports First Quarter 2024 Results
FRIENDSWOOD, Texas, May 02, 2024--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2024.
© 2024 Yahoo. All rights reserved.